GJIA
BMRN icon

Glass Jacobson Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Glass Jacobson Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100
Closed -$9.64K – 756
2023
Q4 		$9.64K Buy
+100
New +$8.85K ﹤0.01% 525

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Glass Jacobson Investment Advisors's BMRN Position: Q1 2024 in Review

Glass Jacobson Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 100 shares — an estimated $9.64K sold.

Glass Jacobson Investment Advisors first reported a position in BMRN in Q4 2023 and held it in 1 quarter. The position peaked at $9.64K in Q4 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Glass Jacobson Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Glass Jacobson Investment Advisors sold 100 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $9.64K.
  • Glass Jacobson Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Glass Jacobson Investment Advisors's BioMarin Pharmaceuticals position peaked at $9.64K in Q4 2023.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Glass Jacobson Investment Advisors's 13F filing for Q1 2024, filed 26 Apr 2024.